TWI615157B - 包括不定形西洛他唑的固體分散劑 - Google Patents

包括不定形西洛他唑的固體分散劑 Download PDF

Info

Publication number
TWI615157B
TWI615157B TW103103097A TW103103097A TWI615157B TW I615157 B TWI615157 B TW I615157B TW 103103097 A TW103103097 A TW 103103097A TW 103103097 A TW103103097 A TW 103103097A TW I615157 B TWI615157 B TW I615157B
Authority
TW
Taiwan
Prior art keywords
cilostazol
solid dispersant
methacrylic acid
acid copolymer
powder
Prior art date
Application number
TW103103097A
Other languages
English (en)
Chinese (zh)
Other versions
TW201440814A (zh
Inventor
川崎淳一
Junichi Kawasaki
中村篤哉
Atsuya NAKAMURA
鎌田直興
Naoki Kamada
Original Assignee
大塚製藥股份有限公司
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大塚製藥股份有限公司, Otsuka Pharmaceutical Co., Ltd. filed Critical 大塚製藥股份有限公司
Publication of TW201440814A publication Critical patent/TW201440814A/zh
Application granted granted Critical
Publication of TWI615157B publication Critical patent/TWI615157B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
TW103103097A 2013-02-06 2014-01-28 包括不定形西洛他唑的固體分散劑 TWI615157B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-021475 2013-02-06
JP2013021475 2013-02-06

Publications (2)

Publication Number Publication Date
TW201440814A TW201440814A (zh) 2014-11-01
TWI615157B true TWI615157B (zh) 2018-02-21

Family

ID=50184966

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103103097A TWI615157B (zh) 2013-02-06 2014-01-28 包括不定形西洛他唑的固體分散劑

Country Status (11)

Country Link
US (1) US9555026B2 (enExample)
EP (1) EP2953615B1 (enExample)
JP (2) JP5980449B2 (enExample)
KR (1) KR102205192B1 (enExample)
CN (1) CN105050586B (enExample)
AR (1) AR095143A1 (enExample)
AU (1) AU2014215920B2 (enExample)
CA (1) CA2899389C (enExample)
PH (1) PH12015501722A1 (enExample)
TW (1) TWI615157B (enExample)
WO (1) WO2014123244A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381945A (zh) * 2017-02-10 2019-10-25 阿尔图姆制药股份有限公司 口服给予的镓（iii）配合物的组合物
KR102114550B1 (ko) * 2018-07-10 2020-05-22 삼육대학교산학협력단 생리학적 체내 동태 연구 모델링을 이용한 약제학적 조성물의 제조 방법
CA3136081A1 (en) * 2019-05-03 2020-11-12 Azora Therapeutics, Inc. Compositions comprising indigo and/or an indigo derivative and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168102A (zh) * 1995-01-10 1997-12-17 大制药株式会社 树脂微粒及含该树脂微粒的药用材料和药剂
WO2009051022A2 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683673A5 (de) * 1991-10-01 1994-04-29 Otsuka Pharma Co Ltd Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug.
JP3799093B2 (ja) * 1995-01-10 2006-07-19 大塚製薬株式会社 樹脂粒状物およびこれを含有する医療製剤
PT784974E (pt) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparacao de derivados de xantina numa dispersao solida
JPH11246404A (ja) 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
JP4748839B2 (ja) 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
CA2508840A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
CN1241566C (zh) * 2004-03-15 2006-02-15 深圳海王药业有限公司 西洛他唑固体分散体及其片剂制备方法
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1970040A4 (en) 2005-12-22 2013-05-29 Otsuka Pharma Co Ltd METHOD FOR PRODUCING MEDICINAL WAX MATRIX PARTICLES, IN THE METHOD OF USING EXTRUDERS AND CILOSTAZOL-CONTAINING PREPARATION WITH DELAYED RELEASE
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US20110165236A1 (en) 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
KR20080076440A (ko) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2008138755A2 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
AR071706A1 (es) 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
TW201010743A (en) * 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
WO2011027656A1 (en) 2009-09-04 2011-03-10 Semiconductor Energy Laboratory Co., Ltd. Transistor and display device
KR101282847B1 (ko) * 2011-07-27 2013-07-05 조선대학교산학협력단 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1168102A (zh) * 1995-01-10 1997-12-17 大制药株式会社 树脂微粒及含该树脂微粒的药用材料和药剂
WO2009051022A2 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Characterization and Controlled Release of Solid Dispersed Cilostazol with Hydrophilic Polymers
Characterization and Controlled Release of Solid Dispersed Cilostazol with Hydrophilic Polymers Der Pharmacia Lettre, 2012, 4(1):42-533 *
Der Pharmacia Lettre, 2012, 4(1):42-533

Also Published As

Publication number Publication date
AU2014215920B2 (en) 2018-03-15
EP2953615B1 (en) 2018-05-23
CN105050586A (zh) 2015-11-11
CN105050586B (zh) 2017-12-08
HK1218618A1 (en) 2017-03-03
TW201440814A (zh) 2014-11-01
EP2953615A1 (en) 2015-12-16
JP2016193915A (ja) 2016-11-17
WO2014123244A1 (en) 2014-08-14
AU2014215920A1 (en) 2015-08-20
PH12015501722B1 (en) 2015-11-09
JP5980449B2 (ja) 2016-08-31
CA2899389C (en) 2021-02-16
AR095143A1 (es) 2015-09-30
JP2016506948A (ja) 2016-03-07
CA2899389A1 (en) 2014-08-14
US20150366859A1 (en) 2015-12-24
KR102205192B1 (ko) 2021-01-20
KR20150115859A (ko) 2015-10-14
PH12015501722A1 (en) 2015-11-09
US9555026B2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
KR101737250B1 (ko) 개선된 생체이용률을 갖는 약학 조성물
EP2589384A1 (en) New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders
JP6522853B2 (ja) Ｓｏｍｃｌ−９１１２固体分散体、その製造方法およびそれを含むｓｏｍｃｌ−９１１２固体製剤
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
US20190231783A1 (en) Pharmaceutical formulations
TWI615157B (zh) 包括不定形西洛他唑的固體分散劑
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
WO2019030691A1 (en) EXTRUDED COMPOSITIONS OF ENZALUTAMIDE
WO2014063596A1 (zh) 一种治疗糖尿病的口服制剂
JP2025526729A (ja) ナポラフェニブを含む非晶質固体分散体
HK1218618B (en) Solid dispersion comprising amorphous cilostazol
CN116492305A (zh) 一种盐酸洛氟普啶片及其制备方法
CN119522100A (zh) 含有德拉马尼的固体分散体
JP2006104194A (ja) 用時調製型レバミピド注腸製剤
HK40012627A (en) Pharmaceutical formulations containing adenosine a2a receptor antagonists

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees